The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.

Abstract

Epithelial ovarian cancer is a heterogeneous disease and many biologic and molecular factors are important for its development and progression, including growth rate, metastatic potential, chemo- and radiosensitivity, and prognosis. Even in the early stages (FIGO I-II), many questions persist about the biologic behavior, optimal treatment, and prognosis. In a series of 106 patients with epithelial ovarian cancers in FIGO stages IA-IIC, a number of known prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to two important growth factor receptors for oncogenesis (HER-2/neu and EGFR). Immunohistochemical techniques were used. All patients received adjuvant radiotherapy 4-6 weeks after the primary surgery. In a univariate analysis, the expression of the HER-2/neu receptor was not associated with any of the clinicopathologic factors studied or survival status. Positive EGFR staining was associated with poor survival in a univariate analysis. Co-expression of HER-2/neu and EGFR was most frequently seen in serous tumors and positive staining for HER-2/neu alone was associated with mucinous tumors. Both endometrioid and clear cell tumors belonged to the largest subgroup with concomitant negativity for both HER-2/neu and EGFR. In a multivariate Cox analysis, the tumor grade and EGFR status of the tumors were independent and significant prognostic factors. A therapeutic strategy for epithelial ovarian cancer might be to decrease EGFR expression by gene therapy in combination with adjuvant radiotherapy or chemotherapy.

• Authors: I Skirnisdóttir, B Sorbe, T Seidal
• Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) 2001 Mar-Apr Vol. 11 Issue 2 Pg. 119-29 ISSN: 1048-891X [Print] England
• PMID: 11328410 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• ErbB Receptors
• Receptor, ErbB-2

Topics

• Biomarkers, Tumor (analysis)
• Carcinoma (pathology, radiotherapy, surgery)
• ErbB Receptors (analysis, physiology)
• Female
• Gene Expression Regulation, Neoplastic
• Humans
• Immunohistochemistry
• Middle Aged
• Neoplasm Staging
• Ovarian Neoplasms (pathology, radiotherapy, surgery)
• Prognosis
• Radiotherapy, Adjuvant
• Receptor, ErbB-2 (analysis, physiology)
• Regression Analysis
• Survival Analysis
• Treatment Outcome